Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Metselex Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending action is assigned to 1 distinct art unit and 1 distinct examiner. The concentration of the workload within 1 art unit suggests a focused prosecution effort at this stage. Practitioners should note that the active portfolio is currently subject to the review of a specific administrative group at the USPTO.
HOWELL, THEODORE R is the busiest examiner for the portfolio, currently handling 1 pending office action. This examiner is responsible for the 1 pending office action identified in the company data. The progress of the company's patent applications is directly tied to this individual's examination pace and requirements.
The Biotechnology & Pharmaceuticals sector represents the current active prosecution front for the company. Successful prosecution will require addressing the concerns of HOWELL, THEODORE R within the assigned art unit. This 1 action represents the primary point of activity for the portfolio's expansion in this technical field. Monitoring the status of the pending office action is essential for understanding the company's near-term intellectual property trajectory.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 1 | 66.9% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18581998 | FLUORINATED AND ALKYLATED BILE ACIDS | HOWELL, THEODORE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18581998 | FLUORINATED AND ALKYLATED BILE ACIDS | HOWELL, THEODORE R | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18581998 | FLUORINATED AND ALKYLATED BILE ACIDS | HOWELL, THEODORE R | 1628 | §101§102DP | Non-Final OA | — | Pending | Feb 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMetselex Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Theodore R Howell has the most, with 1 of Metselex Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
